Cargando…

Prognostic landscape of mitochondrial genome in myelodysplastic syndrome after stem-cell transplantation

Despite mitochondrial DNA (mtDNA) mutations are common events in cancer, their global frequency and clinical impact have not been comprehensively characterized in patients with myelodysplastic neoplasia (also known as myelodysplastic syndromes, MDS). Here we performed whole-genome sequencing (WGS) o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong, Jing, Buradagunta, Christopher Staffi, Zhang, Tao, Spellman, Stephen, Bolon, Yung-Tsi, DeZern, Amy E., Gadalla, Shahinaz M., Deeg, H. Joachim, Nazha, Aziz, Cutler, Corey, Cheng, Chao, Urrutia, Raul, Auer, Paul, Saber, Wael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999628/ https://www.ncbi.nlm.nih.gov/pubmed/36899395 http://dx.doi.org/10.1186/s13045-023-01418-4

Ejemplares similares

Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR study
por: Zhang, Tao, et al.
Publicado: (2023)

Impact of Epigenomic Hypermethylation at TP53 on Allogeneic Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndromes
por: Wang, Wei, et al.
Publicado: (2021)

The Evolving Landscape of Myelodysplastic Syndrome Prognostication
por: Shreve, Jacob, et al.
Publicado: (2020)

Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia
por: Ambinder, Alexander J., et al.
Publicado: (2022)

Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study
por: Abel, Gregory A., et al.
Publicado: (2023)

Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence
por: Nazha, Aziz, et al.
Publicado: (2019)

COVID-19 Outcomes Among Participants in the NHLBI Myelodysplastic Syndromes (MDS) Natural History Study
por: Padron, Eric, et al.
Publicado: (2021)

The spatial arrangement of ORC binding modules determines the functionality of replication origins in budding yeast
por: Bolon, Yung-Tsi, et al.
Publicado: (2006)

Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies
por: Gorak, Edward J., et al.
Publicado: (2023)

Decoupling blood telomere length from age in recipients of allogeneic hematopoietic cell transplant in the BMT-CTN 1202
por: Lai, Tsung-Po, et al.
Publicado: (2022)

The genomic landscape of pediatric myelodysplastic syndromes
por: Schwartz, Jason R., et al.
Publicado: (2017)

A machine learning model of response to hypomethylating agents in myelodysplastic syndromes
por: Radakovich, Nathan, et al.
Publicado: (2022)

Editorial: Advancing Science for Clinical Care in MDS
por: Figueroa, Maria E., et al.
Publicado: (2022)

Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study
por: Dong, Jing, et al.
Publicado: (2022)

Socioeconomic disadvantage contributes to ethnic disparities in multiple myeloma survival: a matched cohort study
por: Buradagunta, Christopher Staffi, et al.
Publicado: (2022)

Polychlorinated Biphenyls and Cancer: Are Telomeres to Blame?
por: Gadalla, Shahinaz M., et al.
Publicado: (2015)

Validation of International Working Group response criteria in higher‐risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium
por: Komrokji, Rami S., et al.
Publicado: (2020)

Assessment of HLA-B genetic variation with an HLA-B leader tool and implications in clinical transplantation
por: Sajulga, Ray, et al.
Publicado: (2022)

Assessment of HLA-DPB1 genetic variation using an HLA-DP tool and its implications in clinical transplantation
por: Sajulga, Ray, et al.
Publicado: (2023)

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
por: Komrokji, Rami S., et al.
Publicado: (2022)

Molecular landscape in acute myeloid leukemia: where do we stand in 2016
por: Al-Issa, Karam, et al.
Publicado: (2016)

CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine
por: Karantanos, Theodoros, et al.
Publicado: (2022)

Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Concurrent Lymphoid Malignancy
por: Zimmerman, Zachary, et al.
Publicado: (2011)

Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study
por: Garcia-Manero, Guillermo, et al.
Publicado: (2021)

Impact of Copy Neutral Loss of Heterozygosity and Total Genome Aberrations on Survival in Myelodysplastic Syndrome
por: Yeung, Cecilia, et al.
Publicado: (2017)

Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
por: Haferlach, T, et al.
Publicado: (2014)

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Savona, Michael R., et al.
Publicado: (2020)

Molecular features of early onset adult myelodysplastic syndrome
por: Hirsch, Cassandra M., et al.
Publicado: (2017)

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts
por: Zeidan, Amer M., et al.
Publicado: (2022)

Are We Ready For “Triplet” Therapy in Higher-Risk MDS?
por: Brunner, Andrew M., et al.
Publicado: (2023)

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
por: Sallman, David A., et al.
Publicado: (2021)

Multicenter Validation Study of a Transplantation-Specific Cytogenetics Grouping Scheme for Patients with Myelodysplastic Syndromes
por: Armand, Philippe, et al.
Publicado: (2009)

Landscape of alterations in the checkpoint system in myelodysplastic syndrome and implications for prognosis
por: Moiseev, Ivan, et al.
Publicado: (2022)

The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia
por: Bănescu, Claudia, et al.
Publicado: (2023)

Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms
por: Gerke, Margo B., et al.
Publicado: (2023)

Sex-Related Differences in Chronic Myeloid Neoplasms: From the Clinical Observation to the Underlying Biology
por: Karantanos, Theodoros, et al.
Publicado: (2021)

DNA-methylation-based telomere length estimator: comparisons with measurements from flow FISH and qPCR
por: Pearce, Emily E., et al.
Publicado: (2021)

Myelodysplastic syndromes: Biological and therapeutic consequences of the evolving molecular aberrations landscape
por: Schwind, Sebastian, et al.
Publicado: (2021)

Elevated TWIST1 expression in myelodysplastic syndromes/ acute myeloid leukemia reduces efficacy of hypomethylating therapy with decitabine
por: Li, Hongjiao, et al.
Publicado: (2020)

Telomere Length Calibration from qPCR Measurement: Limitations of Current Method
por: Wang, Youjin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_73qmobbebvmn0urqs3k7r79ed8